"Doesn't a$2.5 billion market cap seem a little expensive for a company that has not completed a phase 3 trial yet?"
It sure is a large cap for a company without a proven treatment yet, but just goes to show just how massive it will be if they pull it off.
It is hard to think how single blinding could affect the harder end points but full blinding is the best as you say
bio shares dated 26/8/11, page-7
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |